Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05169112 | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | recruiting | Phase 3 | 72 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04100174 | Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy(fBTsRT) | recruiting | Phase 2 | 150 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 |
| clinicaltrials |
| NCT06652607 | PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer(PSA-DEEP02) | recruiting | — | 152 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863090 | In Vivo Dosimetry for Brachytherapy Study | recruiting | — | 20 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06866782 | European Registry of Next Generation Imaging in Advanced Prostate Cancer(RING) | recruiting | — | 600 | Fundacio PuigvertOTHER | 8 | Mar 11, 2025 | clinicaltrials |
| NCT03987633 | EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality(EMPOWER) | recruiting | — | 200,000 | Future Genetics LimitedOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06446401 | The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer(Lead4Care) | recruiting | — | 1,400 | Uppsala UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | recruiting | Phase 3 | 60 | Region VästerbottenOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06783829 | A Study of SHR-4394 Injection in Subjects With Prostate Cancer | recruiting | Phase 1 | 240 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06850545 | Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer(KuPSMALu) | recruiting | — | 150 | Kuopio University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06766526 | Internet-based Support for Adjustment to Prostate Cancer(ISAC) | recruiting | N/A | 180 | Linkoeping UniversityOTHER_GOV | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05000827 | Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients(PSMA-SELECT) | recruiting | N/A | 706 | Canisius-Wilhelmina HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06818682 | Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial(RELAX) | recruiting | Phase 2 | 206 | Tata Memorial CentreOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06820606 | Comparing Rezum and Urolift | recruiting | N/A | 120 | Chinese University of Hong KongOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06259279 | High Impact Training to Patients with Prostate Cancer and Bone Metastases(HIP) | recruiting | N/A | 102 | Copenhagen University Hospital at HerlevOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06612047 | Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer(5TbpMRI) | recruiting | — | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06737588 | The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer | recruiting | — | 600 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06783127 | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer(COROS) | recruiting | — | 3,000 | Santa Chiara HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06820333 | Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer | recruiting | — | 200 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06449781 | 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer(PSMA-ADJUVO) | recruiting | Phase 2 | 200 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04992728 | Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI | recruiting | — | 100 | University of California, San DiegoOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06785441 | Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing | recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06806917 | Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center | recruiting | — | 65 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05381103 | PSMA-PET to Guide Prostatectomy | recruiting | Phase 2 / Phase 3 | 288 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06468332 | Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer(PRISM-AI) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06784986 | Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.(ARCO2) | recruiting | Phase 4 | 200 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06554587 | Investigation of Three Biomarkers for the Detection of Prostate Cancer | recruiting | — | 137 | Medtechtomarket Consulting LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06773598 | Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer | recruiting | — | 1,100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774781 | Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions | recruiting | — | 120 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06756334 | Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis | recruiting | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06398613 | Preoperative PSMA PET/CT As Triage for EPLND in Patients Scheduled for RALP (PrePSMA)(PrePSMA) | recruiting | N/A | 600 | Oslo University HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06748456 | A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice | recruiting | N/A | 50 | University of CopenhagenOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06640959 | Chronic Radiation Induced Bowel Toxicity Study(CRIBS) | recruiting | — | 50 | The Christie NHS Foundation TrustOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06696326 | A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer | recruiting | N/A | 100 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05989854 | The Remote Study: Investigating the Effects or Online Exercise on Quality of Life in Men With Prostate Cancer | recruiting | N/A | 50 | University of SurreyOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06736054 | A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer | recruiting | Phase 1 | 8 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT04113122 | Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study | recruiting | N/A | 192 | University Medical Center GroningenOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06236373 | The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia(Survivorship) | recruiting | — | 45 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02573636 | The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy | recruiting | — | 208 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04896801 | MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days(Proseven) | recruiting | N/A | 132 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05214937 | A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors | recruiting | N/A | 120 | University of TorontoOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06582628 | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)(TEAM PC) | recruiting | Phase 2 | 78 | Fundacion OncosurNETWORK | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06709326 | APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer | recruiting | N/A | 130 | Umeå UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06706921 | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer | recruiting | Phase 4 | 15 | VA Greater Los Angeles Healthcare SystemFED | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05393791 | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC(ANZadapt) | recruiting | Phase 2 | 168 | Leiden University Medical CenterOTHER | 2 | Nov 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2025source: clinicaltrials